Loading
Blacksmith Medicines
Blacksmith Medicines designs drugs against metal-containing enzymes. In cancer it is developing inhibitors of FEN1, a DNA-repair enzyme, to combine with PARP inhibitors in ovarian cancer, and the work is in the laboratory.
Also called: Blacksmith Medicines, Inc.
Overview
Blacksmith Medicines has a chemistry platform for medicines that target human metalloenzymes, with oncology and infectious disease programmes. In oncology it has developed non-hydroxyurea inhibitors of flap endonuclease 1 (FEN1), a DNA-repair metallonuclease with homologous recombination genes among its synthetic lethality partners, and lists QPCTL, which modifies CD47 and CCL2, as a myeloid immunotherapy target. In fiscal year 2026 NCI awarded it USD 399,915 under SBIR award 1R43CA309911-01A1 to combine a selective FEN1 inhibitor with olaparib in PARP inhibitor-resistant ovarian cancer.
Headquarters
San Diego, CA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R43) 1R43CA309911-01A1: Combination of a novel selective FEN1 metallonuclease inhibitor with Olaparib for the treatment of PARP-resistant ovarian cancers | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- No named oncology compound on the company website. Read on blacksmithmedicines.com and NIH RePORTER on 4 November 2026.
Connected
5Similar pages
- TechnologyATR and CHK1 inhibitors
Shares Synthetic lethality approaches, PARP inhibitors, Ovarian cancer.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares PARP inhibitors, Ovarian cancer.
- PersonAlan D. D'Andrea
Shares Synthetic lethality approaches, PARP inhibitors, Ovarian cancer.
- TrialA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Shares PARP inhibitors, Ovarian cancer.
- PersonAlan Ashworth
Shares Synthetic lethality approaches, PARP inhibitors, Ovarian cancer.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares PARP inhibitors, Ovarian cancer.
- CompanyDuke Street Bio
Shares Synthetic lethality approaches, PARP inhibitors, Ovarian cancer.
- TrialA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Shares PARP inhibitors, Ovarian cancer.
cancers
fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
blacksmithmedicines.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/